Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Rayzebio, Inc.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
From Rayzebio, Inc.
Via GlobeNewswire
Tickers BMY RYZB
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Rayzebio, Inc.
Via GlobeNewswire
Tickers RYZB
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
From Rayzebio, Inc.
Via GlobeNewswire
Tickers RYZB
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
From Rayzebio, Inc.
Via GlobeNewswire
Tickers RYZB
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
From Rayzebio, Inc.
Via GlobeNewswire
Tickers RYZB
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
From Rayzebio, Inc.
Via GlobeNewswire
Tickers RYZB
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From RayzeBio, Inc.
Via Business Wire
Tickers RYZB
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
From RayzeBio, Inc.
Via Business Wire
RayzeBio Appoints Christy Oliger to its Board of Directors
From RayzeBio, Inc.
Via Business Wire
RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
From RayzeBio, Inc.
Via Business Wire
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
From RayzeBio, Inc.
Via Business Wire
RayzeBio to Present at Upcoming Medical Conferences
From RayzeBio, Inc.
Via Business Wire
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
From RayzeBio, Inc.
Via Business Wire
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
From RayzeBio, Inc.
Via Business Wire
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
From RayzeBio, Inc.
Via Business Wire
RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023
From RayzeBio, Inc.
Via Business Wire
RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors
From RayzeBio, Inc.
Via Business Wire
RayzeBio to Present at Upcoming Investor Conferences in November 2022
From RayzeBio, Inc.
Via Business Wire
RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer
From RayzeBio, Inc.
Via Business Wire
RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications
From RayzeBio, Inc.
Via Business Wire
RayzeBio Appoints Angie You, Ph.D., to its Board of Directors
From RayzeBio, Inc.
Via Business Wire
RayzeBio Expands Leadership Team with Arvind Kush as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel
From RayzeBio, Inc.
Via Business Wire
RayzeBio to Present at J.P. Morgan Healthcare Virtual Conference on Tuesday, January 11, 2022
From RayzeBio, Inc.
Via Business Wire
RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and Quality
From RayzeBio, Inc.
Via Business Wire
RayzeBio Expands Leadership Team With Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation
From RayzeBio, Inc.
Via Business Wire
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
From RayzeBio, Inc.
Via Business Wire
RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires
From RayzeBio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.